8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
Publication
, Conference
Vredenburgh, JJ; Wefel, J; Cloughesy, T; Zazzali, J; Samant, MK; Zheng, M; Fang, L; Das, A; Friedman, HS
Published in: European Journal of Cancer Supplements
September 2009
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
September 2009
Volume
7
Issue
2
Start / End Page
495 / 496
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J. J., Wefel, J., Cloughesy, T., Zazzali, J., Samant, M. K., Zheng, M., … Friedman, H. S. (2009). 8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. In European Journal of Cancer Supplements (Vol. 7, pp. 495–496). Elsevier BV. https://doi.org/10.1016/s1359-6349(09)71681-7
Vredenburgh, J. J., J. Wefel, T. Cloughesy, J. Zazzali, M. K. Samant, M. Zheng, L. Fang, A. Das, and H. S. Friedman. “8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.” In European Journal of Cancer Supplements, 7:495–96. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71681-7.
Vredenburgh JJ, Wefel J, Cloughesy T, Zazzali J, Samant MK, Zheng M, et al. 8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. In: European Journal of Cancer Supplements. Elsevier BV; 2009. p. 495–6.
Vredenburgh, J. J., et al. “8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.” European Journal of Cancer Supplements, vol. 7, no. 2, Elsevier BV, 2009, pp. 495–96. Crossref, doi:10.1016/s1359-6349(09)71681-7.
Vredenburgh JJ, Wefel J, Cloughesy T, Zazzali J, Samant MK, Zheng M, Fang L, Das A, Friedman HS. 8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. European Journal of Cancer Supplements. Elsevier BV; 2009. p. 495–496.
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
September 2009
Volume
7
Issue
2
Start / End Page
495 / 496
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis